DURHAM, North Carolina, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Read more »
Fortrea Expande Equipe Executiva, Nomeia Oren Cohen como Diretor Médico e Scott Dove como Presidente dos Serviços de Farmacologia Clínica
DURHAM, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Read more »
Fortrea renforce son équipe de direction en nommant Oren Cohen au poste de directeur médical et Scott Dove à celui de président des services de pharmacologie clinique
DURHAM, Caroline du Nord, 17 févr. 2026 (GLOBE NEWSWIRE) -- Read more »
Fortrea Expands Executive Team, Appointing Oren Cohen as Chief Medical Officer and Scott Dove as President of Clinical Pharmacology Services
DURHAM, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Fortrea [...] Read more »
Fortrea Announces Date for Fourth Quarter and Full Year 2025 Financial Results and Conference Call
DURHAM, N.C., Jan. 29, 2026 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its fourth quarter and full [...] Read more »
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
- REC–4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)
- After 12 weeks [...] Read more »
Miltenyi Biomedicine stellt die Primäranalyse der zulassungsrelevanten DALY-2-EU-Studie zur Zweitlinientherapie des rezidivierten/refraktären großzelligen B-Zell-Lymphoms auf der 67. Jahrestagung der American Society of Hematology (ASH) vor
- Die Ergebnisse der DALY 2–EU–Studie zeigen, dass Zamtocabtagen Autoleucel (Zamto–cel) bei Patienten mit rezidiviertem/refraktärem [...] Read more »
À l’occasion de la 67e réunion annuelle de l’American Society of Hematology (ASH), Miltenyi Biomedicine présente l’analyse primaire de l’essai pivot DALY 2-EU pour le traitement de seconde ligne du lymphome à grandes cellules B en rechute ou réfractaire
- Les résultats de l’essai DALY 2–EU révèlent que le zamtocabtagene autoleucel (zamto–cel) présente une [...] Read more »
Miltenyi Biomedicine divulga análise primária do estudo principal do DALY 2-EU para linfoma de células B grandes recidivante/refratário de segunda linha na 67ª Reunião Anual da Sociedade Americana de Hematologia (ASH)
- Os resultados do DALY 2–UE mostram que o autoleucel de zamtocabtageno (zamto–cel) demonstrou superioridade clinicamente significativa em [...] Read more »
Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting
- DALY 2–EU results show zamtocabtagene autoleucel (zamto–cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B–cell lymphoma [...] Read more »